In this commentary, we review clinical data which helps inform individualized benefit–risk
assessment for tofacitinib in patients with psoriatic arthritis (PsA) and ankylosing spondylitis (AS…

Tofacitinib was the first Janus kinase inhibitor to be approved for the treatment of rheumatoid
arthritis (RA), and there is a large body of data to inform the efficacy and safety of this drug …

The use of telemedicine dates as far back as 50 years ago, when the University of Nebraska
used interactive telemedicine to transmit neurologic examinations. 1 Since that time, despite …

Psoriatic arthritis (PsA), a chronic inflammatory joint disease associated with psoriasis, is
notable for diversity in disease presentation, course and response to treatment. Equally varied …

Background: In patients with rheumatoid arthritis (RA), persistent inflammation and increasing
disease activity are associated with increased risk of adverse events (AEs). Objectives: To …

The spread of COVID-19 in the United States has led to the use of virtual visits in lieu of in-person
care for the high-risk population of patients in rheumatology. We asked patients to …

… Hansen, Mahta Mortezavi, Edward Nagy, Cunshan Wang, Carol A. Connell, Zaher Radi,
Heather J. Litman, Giovanni Adami, Maurizio … Hansen, Mahta Mortezavi … Mahta Mortezavi …

As the numbers of cases of COVID-19 continue to rise, the heterogeneity of its clinical
manifestation continues to increase. Here, we describe a case of delayed-onset, biopsy-proven …

The discovery of Janus kinase (JAK) proteins in the early 1990s, 1 which led to the approval
of tofacitinib in rheumatoid arthritis (RA) decades later, serves as an illustrative case study of …

Background Despite effective vaccines and treatments for COVID-19, clinical burden
persists. An unmet need exists for additional effective agents with safety profiles allowing use …